Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective

BACKGROUND: Biological therapy has revolutionized the treatment of inflammatory bowel disease (IBD). After the expiration of patents for biological innovator products, development of biosimilars increased. CT-P13 was the first biosimilar approved for the same indications as the reference product; ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Milassin, Ágnes, Fábián, Anna, Molnár, Tamás
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469269/
https://www.ncbi.nlm.nih.gov/pubmed/31019554
http://dx.doi.org/10.1177/1756284819842748

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469269/
https://www.ncbi.nlm.nih.gov/pubmed/31019554
http://dx.doi.org/10.1177/1756284819842748

Ejemplares similares